The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
one person's 400 is not another person's 400 because and I I know you talk about this a lot about carrier proteins, but also there's the the um genetic differences in the receptor itself, which is the KAG repeat, which predict >> the binding >> the the efficiency of its ability to transcribe um the androgen responsive proteins and just the overall concentration.
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.